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2154while platelet aggregation returned to baseline after
7 to 8 weeks (5). We also demonstrated a progressive
reduction in platelet sensitivity to aspirin in long-
term aspirin-treated patients.
The genomic response to a pharmacological “chal-
lenge” with aspirin has also been demonstrated. After
aspirin administration, a set of platelet-enriched
genes and proteins associated with platelet function
and cardiovascular complications have been identi-
ﬁed. Moreover, increased platelet expression of
glycoprotein IIIa with aspirin treatment has been
demonstrated.
In conclusion, we suggest a better deﬁnition of the
impact of prior aspirin use, because the capability of
aspirin in changing protein platelet expression may
be useful to better understand high on-aspirin treat-
ment platelet reactivity.*Fabio M. Pulcinelli, MD
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REPLY: Aspirin Treatment and OutcomesAfter Percutaneous Coronary Intervention
Results of the ISAR-ASPI RegistryWe thank Dr. Pulcinelli and colleagues for their in-
terest in our publication (1). The high proportion of
patients (>90%) presenting on aspirin therapy in our
cohort likely would not enable a reliable analysis of
the role of the presence or absence of this therapy on
the platelet response to aspirin as measured in this
study.However, the fact that a signiﬁcantly lower pro-
portion of patients taking aspirin showed high on-
aspirin platelet reactivity (91.2% in patients with
vs. 93.8% in those without high on-aspirin platelet
reactivity; p ¼ 0.0006) does not support the authors’
hypothesis. In addition, as mentioned in the results
section of our paper (1), prior aspirin therapy was also
included in the multivariate model for the primary
outcome, the composite of death or stent thrombosis
at 1 year. From this model, prior aspirin therapy
was associated with an adjusted hazard ratio of 0.66
(95% conﬁdence interval: 0.45 to 0.96; p ¼ 0.03) for
the occurrence of the primary outcome, suggesting a
protective role against ischemic events.*Katharina Mayer, MD
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Myocardial AtrophyMechanical unloading using left ventricular assist
devices (LVADs) induces reverse remodeling of the
failing myocardium to levels that are possibly supe-
rior to any other strategy. However, evidence of a
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2155signiﬁcant and reliable curative efﬁcacy is scarce.
This paradox is explained by insufﬁcient and/or
possibly detrimental effects of mechanical unloading,
despite a regression of pathological changes from the
subcellular to the multicellular level. Because a
reduction of cardiomyocyte size is a universal ﬁnding
after LVAD treatment, we and others have called this
effect “atrophy,” which indicates a set of features that
make myocyte mass and function inadequate to sustain
the workload of the heart when it is reloaded. In the
paper by Diakos et al. (1) published in the Journal,
the effect of LVAD treatment on myocardial atrophy
was speciﬁcally investigated, and it was concluded
that no atrophy occurred in these patients. In this
paper, atrophy was predominantly deﬁned as the
evidence of subnormal cardiomyocyte size. A set of
associated parameters were also considered, and we
congratulate the investigators for the substantial set
of data and the effort to further characterize this
interesting population of patients. However, we have
some concerns on the interpretation of the data
presented.
This was not the ﬁrst study to investigate the effect
of unloading of the failing hearts on myocardial at-
rophy. We and others measured myocyte size after
LVAD treatment in patients and found similar results
(2). We also performed several studies using the rat
heterotopic abdominal heart transplantation (HAHT)
model in normal and failing hearts. HAHT induces a
very substantial degree of unloading, and we showed
that this could reverse the hypertrophic response of
an established model of murine heart failure after
1 week of unloading and also induce substantial
myocyte atrophy, to subnormal levels, of normal and
failing myocytes after 4 weeks of unloading (3). This
suggests that the degree of atrophy depends, not
surprisingly, on the degree of unloading.
More than 10 years ago, we showed that, in patients
treated with combined LVAD and pharmacological
therapy, including clenbuterol, the maintenance of
normal cell size was not a determinant of clinical re-
covery. Rather, functional improvements in excita-
tion–contraction coupling were associated with
clinical recovery, which suggested that even amyocyte
of normal size can be dysfunctional (2). We also
showed that reductions in cell size, within certain
limits from normal, did not produce dysfunction and
could even be associatedwith functional improvement
in failing myocytes after unloading (3). We termed this
“physiological” hypotrophy or atrophy, suggesting
again that the absolute cell size is not deterministic
of cell function, and that the consequences of the
reduction in cell size depend upon the pathological
substrate.Another concern regarding this study was that most
of the experiments showed only values before and
after LVAD, and did not compare these values with the
normal myocardium. Considering that the pre-LVAD
samples represent a substantially diseased tissue,
the lack of improvement in ultrastructural features,
for example, suggests a lack of cellular recovery.
Furthermore, with the evidence that hypertrophy and
atrophy share a number of signalling pathways (4),
the lack of difference between pre- and post- LVAD
does not rule out atrophy. In addition, with respect
to t-tubules, the investigators limited their analysis
to the distance of ryanodine receptors from the
sarcolemma—which was used as an index of atrophy
for an unclear reason—with no reference to the
parameters that were associated with cellular func-
tions, including calcium handling (density, regu-
larity, morphology, and local excitation–contraction
coupling) (5). We showed that t-tubular disruption is a
feature of both overloaded and unloaded dysfunc-
tional myocardium, and the current ﬁndings would
be consistent with the dysfunction of overload
(pre-LVAD) and atrophy (post-LVAD) (5). The diver-
gence of these data might be partly ascribed to the
heterogeneity of the patient population, together with
differences in unloading and/or pharmacological
management.
We suggest that the current data should not be used
as an indication of normalization of function and lack
of atrophy, but rather as further evidence that current
clinical strategies of mechanical unloading are insuf-
ﬁcient to produce meaningful recovery of the
myocardium. More studies are needed to optimize
these strategies and explore associated therapies.*Cesare M. Terracciano, MD, PhD
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REPLY: Does Size Matter?In Search of a Physiological Deﬁnition of
Myocardial AtrophyWe would like to thank Dr. Terraciano and col-
leagues for their interest in our study (1). The aim of
our study was to: 1) address the long-standing issue
of whether myocardial atrophy and degeneration
could be induced as a result of prolonged ventricu-
lar assist device (VAD) unloading; and 2) address
this issue by studying the effects of newer genera-
tion, continuous-ﬂow VADs. Previous studies that
used ﬁrst-generation pulsatile VADs reported effects
on myocardial hypertrophy (2). These studies did
not focus on investigating myocardial atrophy and
degeneration.
One aspect of our research approach was to deﬁne
and try to identify atrophy pathologically both at the
cellular and subcellular levels using digital histopa-
thology, confocal microscopy, and electron micro-
scopic analysis (methodologies thatwere standardized
in previous publications from our group). Our ex vivo
structural data were also supported by the in vivo
echocardiographic data, which showed no left ven-
tricular (LV) mass reduction to levels lower than the
normal range and no LV function decline indicative
of atrophy and degeneration. Along the same lines, we
did not observe metabolic changes (e.g., excessive
glycogen accumulation) that would have been an
indication of atrophic remodeling.
Regarding the t-tubule microstructural analysis,
we agree with Dr. Teracciano and colleagues that our
approach is a starting point in the quest to under-
stand remodeling in VAD patients at the subcellular
level. Based on our recent work, we think that the
applied t-tubule–ryanodine receptor relationship is
a powerful concept for characterizing the t-system
and associated functional remodeling. Speciﬁcally,
we introduced the t-tubule–RyR relationship as aquantitative marker of subcellular structural remod-
eling of the failing heart and restoration after cardiac
resynchronization therapy (3). In our recent study on
local depletion of the t-system in ventricular myo-
cytes, we found that this structural marker could
also help explain deﬁciencies in excitation–contrac-
tion coupling (4). These studies motivated us to
apply this marker in the investigations on the
myocardial tissue from VAD patients. Unlike the
disruption of the t-tubule system that was observed
by Ibrahim et al. (5) in rat hearts that were fully
unloaded (and denervated) after heterotopic trans-
plantation, in the case of the partial unloading
induced by VADs, we did not observe any t-tubule
system changes that would indicate atrophic
remodeling. As shown by Ibrahim et al. (5) in their
rodent model, “the degree of atrophy depends on the
degree of unloading.” The major differences in the
degree of unloading between the heterotopic trans-
plantation model and the VAD-induced unloading
could explain the differential results. Also, the het-
erotopically transplanted rat hearts had a heart fail-
ure (HF) history of only 4 weeks versus the
chronically ill human hearts of end-stage VAD pa-
tients, which could have also played a role in the
differential response.
In an effort to investigate whether signaling path-
ways associated with atrophic remodeling were acti-
vated, we performed an extensive molecular analysis.
We did not ﬁnd any gene and protein expression
changes that were indicative of active atrophic
remodeling. We acknowledge that these pathways are
complex and not only associated with atrophic
remodeling. For this reason, we did not interpret the
molecular data as isolated evidence, but we did inter-
pret it in conjunction with the structural, t-system
microstructural, ultrastructural, metabolic, and echo-
cardiographic functional phenotypes.
We also analyzed tissue specimens from 18 normal
donor human hearts, and we believe this is one of the
strengths of our study, which has seldom been seen
in similar investigations due to a lack of available
normal heart tissue. In our study, the myocardial
structural analysis that was central for this investi-
gation was performed in this sizeable cohort of
normal donor heart specimens and in the remaining
assays in as many normal heart samples as feasible.
We strongly agree that our data must not be used as
an indication of normalization of cardiac function.
The aim of this study was to investigate whether VAD-
induced unloading could be detrimental and lead to
atrophic remodeling and degeneration. We included
patients who were unloaded with continuous-ﬂow
VAD for up to 1 year, and the evidence presented
